JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.45 -0.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.45

Max

21.45

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-3.62% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.68
Ankstesnė uždarymo kaina	21.45

Naujienos nuotaikos

By Acuity

50%

201 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-29 23:53; UTC

Uždarbis

Naver Posts Weaker First-Quarter Earnings

2026-04-29 23:41; UTC

Karštos akcijos

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

2026-04-29 23:55; UTC

Uždarbis

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-29 23:54; UTC

Uždarbis

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

2026-04-29 23:52; UTC

Uždarbis

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

2026-04-29 23:51; UTC

Uždarbis

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

2026-04-29 23:51; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

2026-04-29 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

2026-04-29 23:22; UTC

Uždarbis

China Longyuan 1Q Net CNY1.70B, Down 14%

2026-04-29 23:22; UTC

Uždarbis

China Longyuan: Power Generation Down 2.9% as of End-March

2026-04-29 23:20; UTC

Uždarbis

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

2026-04-29 23:20; UTC

Uždarbis

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Loss Narrows>000002.SZ

2026-04-29 23:18; UTC

Uždarbis

Naver1Q Net Profit Missed FactSet-Compiled Consensus

2026-04-29 23:17; UTC

Uždarbis

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

2026-04-29 23:15; UTC

Uždarbis

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

2026-04-29 23:15; UTC

Uždarbis

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

2026-04-29 23:13; UTC

Uždarbis

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

2026-04-29 23:12; UTC

Uždarbis

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

2026-04-29 23:11; UTC

Uždarbis

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

2026-04-29 23:11; UTC

Uždarbis

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

2026-04-29 23:04; UTC

Uždarbis

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

2026-04-29 23:04; UTC

Uždarbis

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-3.62% į apačią

12 mėnesių prognozė

Vidutinis 20.75 USD -3.62%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

201 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.